Skip to main content
OpenTrials
Completed

NCT Number: NCT07069868

Telehealth in an Ambulatory Oncology Phase I Clinical Trial Unit

The study aimed to evaluate the feasibility, acceptability, satisfaction and effectiveness of telehealth on early identification and mitigation of adverse events during cycle one of a Phase 1 oncology clinical trial.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Massachusetts General Hospital

Boston, Massachusetts, 02114, United States

About this study

Oncology patients in Phase 1 clinical trials receive study medications administered for the first time in humans. Participants need to be monitored closely for adverse events which can be serious and have critical implications.

A single group repeated measures design was used to evaluate the effect of telehealth on patient outcomes and patient experience for up to four telehealth sessions and nursing staff perceptions of telehealth. Enrollment was limited to 21 participants, in order to limit the number of patients for a pilot study.

Telehealth sessions began within seven days after the initial treatment and occurred weekly during cycle one of the participant's Phase 1 protocol. Side effects assessed by nursing included mucositis, nausea, vomiting, constipation, diarrhea, dyspnea, cough, rash, pain and fever. Patients were also given the opportunity to address other symptoms.

Original research was required to establish validity of telehealth for managing adverse events, dose limiting toxicities of study medications, and enhancing safe clinical care with potentially meeting unmet patient needs when beginning an oncology Phase 1 clinical trial.

Data Collection tools included:

  • Data collection Table which includes variables, sources of data and timeframes
  • Charlson Comorbidity Index (CCI)
  • Patient Reported Outcomes-Common Terminology for Adverse Events (PRO-CTCAE)
  • Adverse Event for Mucositis
  • Adverse Event for Nausea
  • Adverse Event for Vomiting
  • Adverse Event for Constipation
  • Adverse Event for Diarrhea
  • Adverse Event for Dyspnea
  • Adverse Event for Cough
  • Adverse Event for Acneiform Rash
  • Adverse Event for Maculo-Papular Rash
  • Adverse Event for Pain
  • Adverse Event for Fever
  • Nursing Perception of Telehealth Survey
  • Feasibility of Intervention Measure (FIM). Nursing Perspective on the Feasibility of Utilizing Telehealth Technology Survey
  • Nursing Experience with Telehealth and Patients' Adverse Events Survey
  • Patient Feasibility Survey
  • Acceptability of Intervention Measure (AIM). Patient Experience with Accessibility Related to Telehealth Sessions
  • Patient Experience with Telehealth Survey

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Cancer diagnosis
  • Consented and registered to a Phase I oncology clinical trial
  • Cycle one patient
  • 18 years of age or older
  • Willing to participate in weekly telehealth sessions during cycle one
  • Patient Gateway account
  • Zoom video application downloaded and installed
  • A reliable internet connection
  • A device with the following requirements

PC/Mac with:

  • Chrome or Firefox as an internet browser
  • Webcam
  • Microphone
  • Speakers or Headphones

iPhone/iPad/Android Device with:

  • The Partners Patient Gateway Application
  • Front facing camera

Exclusion criteria

  • Adults who are unable to consent
  • Individuals younger than 18 years old
  • Pregnant women
  • Prisoners

Treatment and study plan

Telehealth

Other

During cycle one, participants will be asked about fevers, mucositis, nausea, vomiting, constipation, diarrhea, dyspnea, cough, rash, pain and fever. Symptoms will be graded according to Common Terminology Criteria for Adverse Events. A new adverse event of grade one or higher will be reported to a provider. An adverse event grade two or higher above baseline and/or experiencing cancer related symptoms above baseline, the findings will be reported to a Provider.

Other names: Telemedicine

Primary outcomes

  1. The study will be feasible as measured by the Feasibility of Intervention at study completion.

    Time frame: From enrollment to the end of cycle one which can be up to 28 days.

    Measures were scored via a Linkert scale ranging from 1 to 5. The higher the score indicates feasibility. 1 = completely disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree and 5 = completely agree. Feasibility was measured by patients and nurses to see if telehealth would be feasible if implemented in a Phase 1 oncology clinical trial unit.

Secondary outcomes

  1. The study will be acceptable as measured by the Acceptability of Intervention Measure at study completion.

    Time frame: From enrollment to the end of cycle one which can be up to 28 days.

    Measures were scored via a Linkert scale ranging from 1 to 5. The higher the score indicates acceptability. 1 = completely disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree and 5 = completely agree. Acceptability was measured by patients and nurses to see if telehealth would be acceptable for patients and staff in a Phase 1 oncology clinical trial unit.

Sponsors and collaborators

Lead sponsor

Massachusetts General Hospital

Other

Registry information

Official study title

Telehealth as a Nursing Strategy for Monitoring Patients in an Ambulatory Oncology Phase I Clinical Trial Unit

Important dates

Study start
2021
Primary completion
2022
Study completion
2022
First posted
Jul 17, 2025
Registry last updated
Jul 17, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.